Ipilimumab: beside a new treatment under test
229 studies: a new drug, cell therapy or vaccine is what the study tests. Page 3 of 3. Open to participants first (43), then studies with results posted, then the rest; newest registration first within each.
- Ipilimumab (Immunotherapy) and MGN1703 (TLR Agonist) in Patients With Advanced Solid MalignanciesTerminatedNCT02668770Phase 1Report a problem
- Sequential Combo Immuno and Target Therapy (SECOMBIT) StudyCompletedNCT02631447Phase 2Report a problem
- A Study Investigating SGI-110 in Combination With Ipilimumab in Unresectable or Metastatic Melanoma PatientsStatus unknownNCT02608437Phase 1Report a problem
- A Study of BBI608 Administered in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced CancersCompletedNCT02467361Phase 1Report a problem
- Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast CancerActive, not recruitingNCT02453620Phase 1Report a problem
- Pilot Study to Evaluate the Effects of a Vaccine (HSPPC-96) Combined With Ipilimumab in Patients With Advanced MelanomaWithdrawnNCT02452281Phase 1/2Report a problem
- Phase I Clinical Trial of Cryoimmunotherapy Against Prostate CancerCompletedNCT02423928Phase 1Report a problem
- Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced MalignanciesTerminatedNCT02419495Phase 1Report a problem
- A Study of Varlilumab (Anti-CD27) and Ipilimumab and CDX-1401 in Patients With Unresectable Stage III or IV MelanomaTerminatedNCT02413827Phase 1/2Report a problem
- Safety Study of Enoblituzumab (MGA271) in Combination With Ipilimumab in Refractory CancerCompletedNCT02381314Phase 1Report a problem
- Intratumoral CAVATAK (CVA21) and Ipilimumab in Patients With Advanced Melanoma (VLA-013 MITCI)CompletedNCT02307149Phase 1Report a problem
- Safety of UV1 Vaccination in Combination With Ipilimumab in Patients With Unresectable or Metastatic Malignant MelanomaCompletedNCT02275416Phase 1/2Report a problem
- A Study of Combination Treatment With HF10 and Ipilimumab in Patients With Unresectable or Metastatic MelanomaCompletedNCT02272855Phase 2Report a problem
- Nivolumab With or Without Bevacizumab or Ipilimumab Before Surgery in Treating Patients With Metastatic Kidney Cancer That Can Be Removed by SurgeryActive, not recruitingNCT02210117Early Phase 1Report a problem
- Adoptive Therapy Using Antigen-Specific CD4 T-CellsWithdrawnNCT02210104Phase 1Report a problem
- A Study to Assess the Safety and Tolerability of Atezolizumab in Combination With Other Immune-Modulating Therapies in Participants With Locally Advanced or Metastatic Solid TumorsCompletedNCT02174172Phase 1Report a problem
- Galectin Inhibitor (GR-MD-02) and Ipilimumab in Patients With Metastatic MelanomaCompletedNCT02117362Phase 1Report a problem
- Vaccination With Peptides in Combination With Either Ipilimumab or Vemurafenib for the Treatment of Unresectable Stage III or IV Malignant MelanomaCompletedNCT02077114Phase 1Report a problem
- LTX-315 in Patients With Transdermally Accessible Tumours as Monotherapy or Combination With Ipilimumab or PembrolizumabCompletedNCT01986426Phase 1Report a problem
- A Two-arm, Single Center Phase 1b Trial of Bavituximab Plus Ipilimumab in Advanced Melanoma PatientsTerminatedNCT01984255Phase 1Report a problem
- Study of Dabrafenib +/- Trametinib in Combination With Ipilimumab for V600E/K Mutation Positive Metastatic or Unresectable MelanomaCompletedNCT01767454Phase 1Report a problem
- Safety Study of BMS-986015 (Anti-KIR) in Combination With Ipilimumab in Subjects With Selected Advanced TumorCompletedNCT01750580Phase 1Report a problem
- Study of the Combination of Anti-OX40 and Ipilimumab in Patients With Metastatic MelanomaWithdrawnNCT01689870Phase 1/2Report a problem
- A Phase 1/2 Randomized, Blinded, Placebo Controlled Study of Ipilimumab in Combination With Epacadostat or Placebo in Subjects With Unresectable or Metastatic MelanomaTerminatedNCT01604889Phase 1/2Report a problem
- Safety Study of IL-21/Ipilimumab Combination in the Treatment of MelanomaCompletedNCT01489059Phase 1Report a problem
- Autologous TriMix-DC Therapeutic Vaccine in Combination With Ipilimumab in Patients With Previously Treated Unresectable Stage III or IV MelanomaCompletedNCT01302496Phase 2Report a problem
- Safety and Efficacy Study of BMS-908662 in Combination With Ipilimumab in Subjects With Advanced MelanomaCompletedNCT01245556Phase 1Report a problem
- Combination of Anti-CD137 & Ipilimumab in Patients With MelanomaWithdrawnNCT00803374Phase 1Report a problem
- CD19 Chimeric Receptor Expressing T Lymphocytes In B-Cell Non Hodgkin's Lymphoma, ALL & CLLActive, not recruitingNCT00586391Phase 1Report a problem